Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Scandal One Early Challenge For New GSK Chairman

This article was originally published in PharmAsia News

Executive Summary

Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring of the previously announced asset swap with Novartis, and increasing generic competition to its leading products.

You may also be interested in...



GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining

Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.

Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab

With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.

GSK Upbeat On RSV Vaccines, Hepatitis B Therapy

GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel